The Latest Analyst Ratings for Ventyx Biosciences
Portfolio Pulse from Benzinga Insights
Ventyx Biosciences (NASDAQ:VTYX) received mixed analyst ratings in the last quarter with 2 bullish, 1 somewhat bullish, and 3 indifferent. The average 12-month price target is $28.5, a decrease of 36.2% from the previous target of $44.67. Analysts use various methods to determine their ratings, which are opinions and can vary in accuracy.
November 10, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ventyx Biosciences received mixed ratings and a lowered average price target of $28.5, suggesting a cautious outlook from analysts.
The mixed ratings and reduced price target indicate a neutral to slightly negative sentiment among analysts, which could lead to a cautious short-term impact on VTYX's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100